[8-K] AEON Biopharma, Inc. Reports Material Event
AEON Biopharma, Inc. announced its financial results for the full year 2025, reporting a net loss of $39,222 thousand compared to a net income of $42,005 thousand in 2024. Despite the loss and a highly leveraged capital structure, the company advanced its ABP-450 biosimilar program with positive analytical data and favorable FDA feedback, and strengthened its balance sheet through a $6 million PIPE financing and debt reduction. The company expects to complete most analytical comparability work in 2026.
DEC 15·Stock Titan→
AEON Biopharma signs Daewoong note exchange with equity and warrants | AEON SEC Filing - Form 8-K
AEON Biopharma has entered into an Exchange Agreement with Daewoong to convert Daewoong's existing senior secured convertible notes into equity, a new $1.5 million senior secured convertible note, and warrants. This exchange is expected to result in approximately 23.1 million newly issued shares or pre-funded warrants, with Daewoong's ownership capped at 49.99%. The new convertible note features a 15.79% annual interest rate and automatic conversion into equity under specific financing conditions, while the transaction requires stockholder approval.
DEC 15·Stock Titan▲
AEON Biopharma (NYSE: AEON) agrees Daewoong swap cutting over 90% of debt
AEON Biopharma announced a definitive exchange agreement with Daewoong to convert $15 million in convertible notes and accrued interest into new equity, $1.5 million in new notes due 2030, and cash-exercise warrants for 8 million common shares. This transaction, which is subject to stockholder approval, is expected to eliminate over 90% of AEON’s outstanding debt and could provide more than $8 million in additional cash if the warrants are exercised. The deal aims to strengthen Daewoong’s strategic alignment with AEON and significantly transform AEON's capital structure.
